BioMarin Pharmaceutical Inc. (BM8.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:12AM CEST. Market open.
Currency in EUR
Valuation measures4
| Market cap (intra-day) | 14.27B |
| Enterprise value | 14.32B |
| Trailing P/E | 76.94 |
| Forward P/E | 30.67 |
| PEG ratio (5-yr expected) | 0.70 |
| Price/sales (ttm) | 6.36 |
| Price/book (mrq) | 3.05 |
| Enterprise value/revenue | N/A |
| Enterprise value/EBITDA | N/A |
Trading information
Stock price history
| Beta (5Y monthly) | 0.34 |
| 52-week change 3 | -12.31% |
| S&P500 52-week change 3 | 26.27% |
| 52-week high 3 | 90.52 |
| 52-week low 3 | 70.78 |
| 50-day moving average 3 | 79.96 |
| 200-day moving average 3 | 82.29 |
Share statistics
| Avg vol (3-month) 3 | 3 |
| Avg vol (10-day) 3 | 11 |
| Shares outstanding 5 | 189.88M |
| Implied shares outstanding 6 | 190.54M |
| Float 8 | 188.41M |
| % held by insiders 1 | 0.84% |
| % held by institutions 1 | 100.63% |
| Shares short 4 | N/A |
| Short ratio 4 | N/A |
| Short % of float 4 | N/A |
| Short % of shares outstanding 4 | N/A |
| Shares short (prior month ) 4 | N/A |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Currency in USD.Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 8.31% |
| Operating margin (ttm) | 12.09% |
Management effectiveness
| Return on assets (ttm) | 1.77% |
| Return on equity (ttm) | 4.22% |
Income statement
| Revenue (ttm) | 2.47B |
| Revenue per share (ttm) | 13.12 |
| Quarterly revenue growth (yoy) | 8.80% |
| Gross profit (ttm) | N/A |
| EBITDA | 293.47M |
| Net income avi to common (ttm) | 205.46M |
| Diluted EPS (ttm) | 0.98 |
| Quarterly earnings growth (yoy) | 74.40% |
Balance sheet
| Total cash (mrq) | 1.05B |
| Total cash per share (mrq) | 5.51 |
| Total debt (mrq) | 1.1B |
| Total debt/equity (mrq) | 21.61% |
| Current ratio (mrq) | 2.74 |
| Book value per share (mrq) | 26.74 |
Cash flow statement
| Operating cash flow (ttm) | 280.16M |
| Levered free cash flow (ttm) | 64.45M |
© 2024 Yahoo. All rights reserved.